Literature DB >> 25465742

miRNA expression is highly sensitive to a drug therapy in Parkinson's disease.

Anelya Kh Alieva1, Elena V Filatova2, Aleksey V Karabanov3, Sergey N Illarioshkin3, Svetlana A Limborska2, Maria I Shadrina2, Petr A Slominsky2.   

Abstract

BACKGROUND: miRNAs may play a role in the pathogenesis of Parkinson's disease. It is necessary to continue the search for new miRNAs that may affect the development of neurodegeneration in Parkinson's disease.
METHODS: 20 untreated patients with Parkinson's disease and 18 treated patients with Parkinson's disease (Hoehn and Yahr scores 1-2) were studied. An analysis of the levels of 11 miRNAs in the peripheral blood lymphocytes of patients was carried out using reverse transcription followed by real-time PCR.
RESULTS: The levels of miR-7, miR-9-3p, miR-9-5p, miR-129, and miR-132 were increased by more than three times in treated patients with Parkinson's disease compared with those of the controls.
CONCLUSIONS: It is probable that miRNAs are very sensitive to drug therapy and that the effects of therapy observed may be associated with changes in the levels of these miRNAs and their target genes in patients with Parkinson's disease.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Parkinson's disease; Peripheral blood; microRNAs

Mesh:

Substances:

Year:  2014        PMID: 25465742     DOI: 10.1016/j.parkreldis.2014.10.018

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  23 in total

Review 1.  Tiny But Mighty: Promising Roles of MicroRNAs in the Diagnosis and Treatment of Parkinson's Disease.

Authors:  Ying Wang; Zhaofei Yang; Weidong Le
Journal:  Neurosci Bull       Date:  2017-07-31       Impact factor: 5.203

Review 2.  microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.

Authors:  Loredana Leggio; Silvia Vivarelli; Francesca L'Episcopo; Cataldo Tirolo; Salvo Caniglia; Nunzio Testa; Bianca Marchetti; Nunzio Iraci
Journal:  Int J Mol Sci       Date:  2017-12-13       Impact factor: 5.923

3.  Blood Transcriptomic Meta-analysis Identifies Dysregulation of Hemoglobin and Iron Metabolism in Parkinson' Disease.

Authors:  Jose A Santiago; Judith A Potashkin
Journal:  Front Aging Neurosci       Date:  2017-03-29       Impact factor: 5.750

4.  A meta-analysis of public microarray data identifies biological regulatory networks in Parkinson's disease.

Authors:  Lining Su; Chunjie Wang; Chenqing Zheng; Huiping Wei; Xiaoqing Song
Journal:  BMC Med Genomics       Date:  2018-04-13       Impact factor: 3.063

Review 5.  Precision and Personalized Medicine: How Genomic Approach Improves the Management of Cardiovascular and Neurodegenerative Disease.

Authors:  Oriana Strianese; Francesca Rizzo; Michele Ciccarelli; Gennaro Galasso; Ylenia D'Agostino; Annamaria Salvati; Carmine Del Giudice; Paola Tesorio; Maria Rosaria Rusciano
Journal:  Genes (Basel)       Date:  2020-07-06       Impact factor: 4.096

6.  Circulating Inflammatory miRNAs Associated with Parkinson's Disease Pathophysiology.

Authors:  Sara R Oliveira; Pedro A Dionísio; Leonor Correia Guedes; Nilza Gonçalves; Miguel Coelho; Mário M Rosa; Joana D Amaral; Joaquim J Ferreira; Cecília M P Rodrigues
Journal:  Biomolecules       Date:  2020-06-23

Review 7.  Molecular Regulation in Dopaminergic Neuron Development. Cues to Unveil Molecular Pathogenesis and Pharmacological Targets of Neurodegeneration.

Authors:  Floriana Volpicelli; Carla Perrone-Capano; Gian Carlo Bellenchi; Luca Colucci-D'Amato; Umberto di Porzio
Journal:  Int J Mol Sci       Date:  2020-06-03       Impact factor: 5.923

Review 8.  Use of miRNAs as biomarkers in sepsis.

Authors:  Raluca Dumache; Alexandru Florin Rogobete; Ovidiu Horea Bedreag; Mirela Sarandan; Alina Carmen Cradigati; Marius Papurica; Corina Maria Dumbuleu; Radu Nartita; Dorel Sandesc
Journal:  Anal Cell Pathol (Amst)       Date:  2015-06-28       Impact factor: 2.916

9.  MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.

Authors:  Zhen-Xiu Cheng; Wen-Bo Yin; Zhong-Yu Wang
Journal:  Int J Mol Med       Date:  2017-09-07       Impact factor: 4.101

10.  Differential expression of miRNA 155 and miRNA 146a in Parkinson's disease patients.

Authors:  Elisa Caggiu; Kai Paulus; Giuseppe Mameli; Giannina Arru; Gian Pietro Sechi; Leonardo A Sechi
Journal:  eNeurologicalSci       Date:  2018-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.